Ignite Creation Date:
2025-12-25 @ 2:31 AM
Ignite Modification Date:
2025-12-26 @ 1:07 AM
Study NCT ID:
NCT04638634
Status:
TERMINATED
Last Update Posted:
2021-12-10
First Post:
2020-11-19
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
Sponsor:
CSL Behring
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-02-02
Start Date Type:
ACTUAL
Primary Completion Date:
2021-06-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-06-09
Completion Date Type:
ACTUAL
First Submit Date:
2020-11-19
First Submit QC Date:
None
Study First Post Date:
2020-11-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-12-09
Last Update Post Date:
2021-12-10
Last Update Post Date Type:
ACTUAL